AOD-9604 Safety Information
Safety information for AOD-9604, which failed clinical trials but is still sold illegally. Learn why this peptide's development was discontinued and risks of current use.
Safety Overview
AOD-9604 failed Phase 2b/3 clinical trials for weight loss. Despite this, it continues to be sold through unregulated channels.
What the Trials Showed
Efficacy
- Did NOT meet primary endpoint (weight loss)
- No significant separation from placebo
- Development discontinued
Safety in Trials
- Generally well-tolerated short-term
- No diabetogenic effects (unlike full GH)
- No significant IGF-1 elevation
- Injection site reactions
Why It’s Still Risky
Despite the relatively benign trial data:
Unknown Long-Term Effects
- Trials were short-duration
- Chronic use effects unknown
- Development stopped; no further studies
Product Quality
- Only available from unregulated sources
- Purity cannot be verified
- Contamination possible
Wasted Resources
- Spending money on something that didn’t work in trials
- May delay seeking effective treatments
- No benefit demonstrated
WADA Status
AOD-9604 is prohibited in sport despite failing efficacy trials.
The Lesson
AOD-9604 is an example of why regulatory approval matters:
- Looked promising in animals
- Failed in rigorous human trials
- Proper process identified lack of efficacy
This is for educational purposes. AOD-9604 failed clinical trials and is not approved.
Disclaimer: This article is for educational purposes only and does not constitute medical advice. The information presented is based on current research but should not be used for diagnosis, treatment, or prevention of any disease. Always consult a qualified healthcare provider before making health decisions.